Exicure’s Phase 2 Data for Burixafor in Multiple Myeloma Highlights High Success Rate and Rapid Stem Cell Mobilization
89.5% of Participants Hit Stem Cell Collection Goals—What Makes Burixafor Stand Out?
Exicure (NASDAQ:XCUR) is making headlines after presenting positive topline results from its Phase 2 trial evaluating burixafor in combination with propranolol and G-CSF for stem cell mobilization in multiple myeloma patients. Data were unveiled at the 2025 ASH Annual Meeting, showing 89.5% of study participants achieved the primary endpoint of collecting at least 2x106 CD34+ cells/kg within just two leukapheresis sessions. The therapy’s rapid kinetics—peaking within one hour—differentiates it from other CXCR4 inhibitors, allowing for same-day administration and apheresis.
Data Table: Burixafor Phase 2 Outcomes Stand Out Among Heavily Treated Patients
| Parameter | Value |
|---|---|
| Participants (N) | 19 |
| Met Primary Endpoint in =2 Sessions | 89.5% |
| Prior Daratumumab Exposure | 84.2% |
| Success in Prior Daratumumab Group | 87.5% |
| Median Time to Neutrophil Engraftment | 13 days |
| Median Time to Platelet Engraftment | 17.5 days |
| Peak CD34+ Levels Post-Administration | <1 hour |
| Serious Adverse Events (>Grade 2) | None |
Safety Profile Remains Strong Even in Difficult-to-Treat Cohorts
Burixafor’s combination with propranolol and G-CSF was well tolerated. Importantly, there were no burixafor-related adverse events above Grade 2, even among participants with prior exposure to daratumumab—a therapy known to make stem cell collection harder. Notably, 87.5% of patients who had been treated with daratumumab still reached the cell collection target.
Clinical Significance: Differentiated, Rapid Kinetics Offer Efficiency and Convenience
The standout feature is the speed at which stem cells can be mobilized for collection—peak circulating CD34+ cells are observed within an hour of dosing. This opens the door for a streamlined process that could lessen both clinical complexity and patient burden during transplant preparation.
Burixafor’s Pipeline Expands Beyond Multiple Myeloma
While the Phase 2 trial focused on multiple myeloma, Exicure is eyeing broader indications—including sickle cell disease and chemosensitization in acute myeloid leukemia (AML). This positions burixafor as a potentially valuable tool in several hematologic settings, particularly for patients with challenging mobilization histories.
What’s Next for Investors and Patients?
The Phase 2 success signals meaningful clinical progress for Exicure’s burixafor program. Investors and clinicians alike will want to monitor the transition into additional studies and other disease applications. With rapid mobilization kinetics, a clean safety record, and encouraging data in previously hard-to-mobilize patients, burixafor could soon redefine expectations in autologous stem cell transplant preparation. Will these promising results translate into a broader transformation for stem cell collection standards? Only time—and larger trials—will tell.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI